We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc (PALM)

This study has been terminated.
(unable to enroll expected number of subjects)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00981318
First Posted: September 22, 2009
Last Update Posted: June 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Abbott
Information provided by (Responsible Party):
Barry M. Rodwick, M. D., Rodwick, Barry M., M.D.
September 19, 2009
September 22, 2009
June 23, 2015
December 2009
May 2015   (Final data collection date for primary outcome measure)
Virologic response defined as viral load reduction of >/= 1 log [ Time Frame: 48 weeks ]
Same as current
Complete list of historical versions of study NCT00981318 on ClinicalTrials.gov Archive Site
  • Assess proportion of patients with HIV-1 viral load < 48 copies [ Time Frame: 48 weks ]
  • Assess time to loss of virologic response [ Time Frame: 48 weeks ]
  • Assess development of resistance mutations in patients who develop rebound [ Time Frame: 48 weeks ]
  • Compare serum lipid profile changes [ Time Frame: 48 weeks ]
  • Assess safety and tolerability [ Time Frame: 48 weeks ]
  • Assess degree of immune reconstitution [ Time Frame: 48 weeks ]
Same as current
Not Provided
Not Provided
 
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients
This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.
As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications. This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
Drug: lopinavir/ritonavir plus maraviroc
lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
Other Names:
  • Kaletra
  • lopinavir
  • Selzentry
lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
single arm
Intervention: Drug: lopinavir/ritonavir plus maraviroc
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
3
May 2015
May 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV viral load > 1,000 on current antiviral medications
  • No resistance to study medications
  • Over 18 years of age

Exclusion Criteria:

  • Hepatitis B co-infection
  • Pregnancy
  • Previous therapy with either of the study medications
  • Ongoing substance abuse
  • Significant history of other physical disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00981318
Rodwick01
No
Not Provided
Not Provided
Barry M. Rodwick, M. D., Rodwick, Barry M., M.D.
Rodwick, Barry M., M.D.
Abbott
Principal Investigator: Barry M. Rodwick, M. D. Barry M. Rodwick, M. D.
Rodwick, Barry M., M.D.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP